Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) Short Interest Update
by Tristan Rich · The Markets DailyEnzon Pharmaceuticals Inc. (OTCMKTS:ENZN – Get Free Report) was the recipient of a large decline in short interest during the month of June. As of June 15th, there was short interest totaling 137 shares, a decline of 55.8% from the May 31st total of 310 shares. Based on an average daily volume of 3,304 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the shares of the stock are short sold.
Enzon Pharmaceuticals Price Performance
Enzon Pharmaceuticals stock opened at $4.99 on Tuesday. The stock has a market capitalization of $3.70 million, a P/E ratio of -0.73 and a beta of -0.06. Enzon Pharmaceuticals has a 12-month low of $1.50 and a 12-month high of $12.99. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.01 and a quick ratio of 1.16. The firm’s 50-day moving average is $5.82 and its two-hundred day moving average is $5.70.
Enzon Pharmaceuticals (OTCMKTS:ENZN – Get Free Report) last announced its earnings results on Monday, May 4th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter. The company had revenue of $86.54 million for the quarter.
About Enzon Pharmaceuticals
Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.
The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.